MHRA suspends recruitment to COVID-19 hydroxychloroquine trials

This follows the emerging concerns about use of hydroxychloroquine in COVID-19 as well as data from the RECOVERY trial which has provided convincing evidence of no meaningful mortality benefit in hospitalised patients with COVID-19.

Medicines and Healthcare products Regulatory Agency